VAX-24 Pneumococcal Vaccine for Infants

"Patients that hope to be included in this medical study must be over 42 years old and below 89 years of age."

"Our assessment of Experimental: Group 1's safety came out to be a 2, as there is limited evidence available regarding its efficacy but some supporting the substance's security."

"In order to be admitted into this medical trial, candidates must have had the pneumococcal vaccine and should fall between 42 Days and 89 Days of age. This clinical study is seeking approximately 800 participants."

"The trial is currently available at a total of 23 sites, encompassing metropolitan areas such as Washington, Tampa and Chamblee. It's advised that participants select the closest centre to their current location in order to minimize travel requirements."

"Affirmative. According to information posted on clinicaltrials.gov, this research is actively looking for participants as of April 24th 2023. The trial was first announced on March 29th 2023 and plans to recruit 800 patients from 23 different medical centres."

"For this medical trial, a total of 800 participants that meet the pre-established qualifications are required. Patients can sign up for the study from Meridian Clinical Research in Washington D.C and Jedidiah Clinical Research in Tampa, Florida."

"This 7 day clinical trial will evaluate the rate of solicited systemic adverse events following each vaccination. Secondary objectives include measuring any unsolicited AE in between first and 3rd vaccinations, identifying AEs causing discontinuation within 6 months after last vaccine dose, and determining the frequency of new onset chronic illnesses over a similar time frame."